Abstract |
The antitumor effect of reveromycin A (RM-A), an inhibitor of EGF-dependent cell proliferation on murine and human tumor cell lines, was examined in vitro and in vivo, RM-A showed little antitumor effect against three murine tumors tested, but showed strong antitumor effect (a minimum treated/control ratio of 36%) against a human ovarian carcinoma BG-1, which is known to be a transforming growth factor alpha ( TGF-alpha)-secreting and estrogen receptor-expressing cell line. In BG-1 cells, RM-A inhibited the cell proliferation induced by TGF-alpha at the concentration range 30-300 nM, but did not inhibit the proliferation induced by 17 beta-estradiol (E2).RM-A is a possible new antitumor drug with a novel mechanism of action and may also be a useful tool for the analysis of epidermal growth factor receptor (EGFR)-mediated cell proliferation in tumor cells.
|
Authors | H Takahashi, Y Yamashita, H Takaoka, J Nakamura, M Yoshihama, H Osada |
Journal | Oncology research
(Oncol Res)
Vol. 9
Issue 1
Pg. 7-11
( 1997)
ISSN: 0965-0407 [Print] United States |
PMID | 9112255
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Growth Inhibitors
- Pyrans
- Spiro Compounds
- Transforming Growth Factor alpha
- reveromycin A
|
Topics |
- Animals
- Antibiotics, Antineoplastic
(pharmacology)
- Carcinoma
(drug therapy)
- Cell Division
(drug effects)
- Female
- Growth Inhibitors
(pharmacology)
- Humans
- Mice
- Ovarian Neoplasms
(drug therapy)
- Pyrans
(pharmacology)
- Spiro Compounds
(pharmacology)
- Transforming Growth Factor alpha
(pharmacology)
- Tumor Cells, Cultured
|